Abstract: A semiconductor device includes a semiconductor substrate, a phase change switching device formed over the semiconductor substrate and including a strip of phase change material connected between an RF input contact and an RF output contact, and a heating element thermally coupled to the strip of phase change material, and a silicon adhesion layer that forms a direct interface with a first surface of the strip of phase change material and separates the first surface from a dielectric material formed thereon.

Abstract: The present invention relates to a low profile clamp in which one or both contact surfaces of upper and lower circumferential end portions have a non-flat and preferably complementary cross-sectional shape in the width direction of the band material. Thereby, sliding contact of the upper contact surface on the lower contact surface provides a self-centering effect of the band end portions during a band closing action.

Abstract: A first enzymatic method for the production of an L-glufosinate P-ester includes reacting an L-glufosinate P-ester carbamoylate to give the corresponding L-glufosinate P-ester in the presence of a carbamoylase as a catalyzer. A second enzymatic method includes the enantioselective production of an L-glufosinate P-ester from a mixture MIIIA of L- and D-glufosinate P-ester hydantoins. The L-glufosinate P-ester obtained in the two methods may be saponified to give L-glufosinate.

Abstract: Various embodiments of the teachings herein include an insulation system. An example includes a polymer blend in the form of a solid two-dimensional insulation material, a material for wire insulation by means of extrusion and/or an injection-molded and/or compression-molded article. The blend is resistant to partial discharges and at least partly replaces any mica content in the insulation system. The blend comprises at least three blend partners including at least one copolymer based on polyetherimide and siloxane blended with at least two high-temperature thermoplastics. At least of one the high-temperature thermoplastics is in semicrystalline form, such that spherulites are detectable in the polymer blend.

Abstract: A measurement device for process metrology, includes: a number n of sensors, wherein a respective sensor of the number n of sensors is designed to generate associated sensor data such that a total number n of sensor data is generated by way of the number n of sensors; a learning unit, wherein the learning unit is designed to calculate values of a number d of parameters of a hypothesis function based on training data; and a measurement device diagnostic unit, which is designed to calculate a number m of diagnostic values in dependence on the number n of sensor data based on the hypothesis function and the calculated values of the number d of parameters of the hypothesis function.

Abstract: A housing of an electrical device for converting electrical power has a main body with a rear wall, side walls and a cover. The cover and body define a an interior space. Components of the electrical device are arranged in the interior space. The cover is connected to the body by a cover closure that includes a fastening structure and a closure housing. The fastening structure is retained in the closure housing, which is fastened to the cover. The body includes a pin that extends from the rear wall of the housing to the cover. A connection between the cover and pin is releasable by turning the fastening structure using a guide peg of the pin and a helically encircling guide groove of the fastening structure.

Abstract: The present invention provides for parenterally administrable live attenuated influenza immune compositions. Methods of using parenterally administrable live attenuated influenza immune compositions to elicit an immune response, and particularly, a protective immune response are also provided.

Abstract: The present invention is the use of designed recombinant viruses for the treatment of various forms of malignant tumors. The recombinant viruses of the invention are those in which one or more regions of the wild type virus was exchanged with a synthetic recoded sequence that reduces the codon pair score relative to human codon pair bias, or that increase the number for CpG di-nucleotides, or that increases the number of UpA di-nucleotides. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, as well as for the treatment of breast cancer and melanoma as well.

Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.

Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K) L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.

Abstract: The present invention provides for modified Flavivirus such as a modified Zika virus. The modification according to various aspects of the invention results in reduced viral proteins compared to a parent virus, wherein the reduction in expression is the result of recoding one or more regions of the virus. For example, the prM, or envelope (E) region, or the nonstructural protein 3 (NS3) region or both the E and NS3 regions can be recoded. In various embodiments one or more regions are recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. These modified Flavivirus are used as vaccine compositions to provide a protective immune response.

Abstract: Technologies and techniques for the at least the partially automated driving of a motor vehicle. A first application and at least one redundant second application provide output data depending on motor vehicle operating data and/or environmental data. Vehicle driving data for the at least partially automated driving of the motor vehicle are determined depending on the output data. Vehicle operating data from another vehicle are received, and, depending on the vehicle operating data, the at least one redundant second application switches from an active state to a standby state in which a computer instance of a computer unit used by the at least one redundant second application is at least executed at a lower frequency than in the active state.

Abstract: The present disclosure provides methods for treating one or more grains in an ethanol plant or alcohol brewery, methods of drying, cooling, disease control of dried distillers grains with soluble (DDG), barley, or brewer's spent grain (BSG), and a system for treating one or more grains in an ethanol plant or alcohol brewery by these disclosed methods.

Abstract: Described herein are modified SARS-CoV-2 variants. These viruses have been recoded, for example, codon deoptimized or codon pair bias deoptimized and are useful for reducing the likelihood or severity of a SARS-CoV-2 variant infection, preventing a SARS-CoV-2 variant infection, eliciting and immune response, or treating a SARS-CoV-2 variant infection.

Abstract: The present invention relates to deoptimized Yellow Fever viruses and their uses for the treatment of various forms of malignant tumors, and as vaccines against Yellow Fever. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain.

Abstract: The invention relates to novel compounds of the formula (I) in which A1, A3, X, R1, R3, R4, R6, R7, R8 and n have the definitions given above, to the use thereof as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for preparation thereof.

Abstract: The disclosure relates to a transceiver device for communicating between a network protocol controller and a network bus, the transceiver device comprising: transceiver circuitry configured to transmit and receive data on the network bus using a first physical layer protocol; and monitoring circuitry configured to determine a measured property of the network bus, in which the transceiver device is configured to: determine whether the measured property indicates an error condition; and reconfigure the transceiver circuitry to transmit and receive data on the network bus using a second physical layer protocol in response to determining the error condition.

Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.

Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.